Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

November 26, 2019December 18, 2019

Fintepla Lowers Seizure Frequency in Children and Teens with Dravet, Phase 3 Studies Report

News

Editor’s note: This story has been updated to add that Zogenix resubmitted a new drug application for Fintepla to the FDA in late September. Treatment with Fintepla (ZX008) can ... Read more

October 29, 2019October 29, 2019

NeuCyte, Trillium Therapeutics Team Up to Develop New Therapy for Drug-resistant Epilepsies

News

Neucyte and Trillium Therapeutics have established a license agreement to develop a new therapy for drug-resistant epilepsies, including Dravet syndrome and related disorders. The agent, whose name is still undisclosed, ... Read more

August 27, 2019August 27, 2019

Stoke Therapeutics’ STK-001 Granted Orphan Drug Designation by FDA

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation — allowing various development incentives — to Stoke Therapeutics’ STK-001 for the treatment of Dravet syndrome. The ... Read more

August 20, 2019October 8, 2019

EU Approval of Oral Cannabidiol as Add-On Therapy for Dravet Favored by CHMP

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), is recommending approval of GW Pharmaceutical’s oral cannabidiol solution as an add-on to clobazam (Onfi and Sympazan) for treating seizures ... Read more

July 23, 2019July 23, 2019

Encoded Earns $104M in Financing to Advance Potential Gene Therapy for Dravet

News

Encoded Therapeutics will further develop its lead precision gene therapy platform for Dravet syndrome and other severe genetic disorders after a financing round brought in $104 million from several ... Read more

July 9, 2019July 9, 2019

Zogenix Resubmitting New Drug Application to FDA for Fintepla Anti-Seizure Therapy

News

Zogenix has announced it will resubmit a New Drug Application (NDA) for Fintepla (ZX008), its investigational anti-seizure therapy for patients with Dravet syndrome, likely in the third quarter of this ... Read more

July 2, 2019October 8, 2019

Epygenix Submits Investigational New Drug Application for Dravet Therapy

News

Epygenix Therapeutics has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to assess the safety and efficacy of EPX-100, its investigational ... Read more

March 26, 2019March 26, 2019

Nippon Shinyaku to Market Fintepla in Japan for Treatment of Dravet Syndrome Seizures

News

Zogenix‘s investigational therapy Fintepla (ZX008) to treat epileptic seizures associated with Dravet syndrome will be marketed in Japan by pharmaceutical company Nippon Shinyaku. Fintepla is a low-dose oral solution of fenfluramine ... Read more

October 4, 2018October 4, 2018

FDA Approves Fycompa for Treatment of Focal Seizures in Children Ages 4 and Older

News

The U.S. Food and Drug Administration has approved Fycompa (perampanel) — alone or as an add-on — for the treatment of focal seizures, which affect only one part of the ... Read more

November 7, 2018November 7, 2018

Epidiolex Now Available in the U.S. for Lennox-Gastaut and Dravet Patients 2 and Older

News

Epidiolex (cannabidiol) oral solution is now available in the United States as a treatment for seizures in patients age 2 or older who have Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex is developed ... Read more

Pin It on Pinterest